Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, has been registered by the TGA for the treatment of Australian adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a)
- Welcome to Specialised Therapeutics
-
SE Asia
+65 3158 9940
-
1300 798 820
-
New Zealand
+64 9801 0299
Tafasitamab - Specialised Therapeutics
October 22, 2021
Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies
Singapore, 22 October 2021: Independent pharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two new medicines for its haematology and oncology portfolios, tafasitamab (sold as Monjuvi® in the United States and Minjuvi® in Europe) and pemigatinib (Pemazyre®). Under the
August 6, 2019
New Drug for Diabetes-Induced Vision Loss TGA-Approved for Australian patients
Melbourne, Australia and Atlanta, Georgia, 5 August 2019: Australian patients with diabetes-induced eye disease can now access a new treatment option that provides consistent and continuous treatment with long-lasting effect. The Therapeutic Goods Administration has now approved the drug ILUVIEN® (fluocinolone acetonide intravitreal implant), which delivers fluocinolone acetonide via a sustained release implant and provides therapeutic effect
May 17, 2019
Specialised Therapeutics Asia Unveils ‘Track and Trace’ Pharma Model to Boost Drug Security, Improve Patient Safety
Singapore, 17 May 2019: Independent pharmaceutical company Specialised Therapeutics Asia (STA) is launching an innovative tracking system that will enable real time monitoring of every unit of drug product provided through its supply chain – from packing to patient. The company, which markets specialist medicines to patients in Australia, New Zealand and across South East Asia,
March 19, 2019
New Early Breast Cancer Drug to Reduce Risk of Recurrence or Death Approved for Australian Women
19 March 2019: A NEW drug shown to significantly reduce the risk of cancer recurrence or death in an aggressive form of breast cancer has today been approved for use in Australian patients. The drug, NERLYNX (neratinib) is an oral medication taken for 12 months by women with early stage HER2-positive (HER2+) breast cancer. It is
February 18, 2019
New Early Breast Cancer Drug to Be Made Available in Singapore via Special Access Program
Singapore, 18 February 2019: A NEW breast cancer drug shown to significantly reduce the risk of cancer recurrence is being made available to women in Singapore from today via a Special Access Program. The drug, NERLYNX (neratinib) is an oral medication taken by women with HER2+ breast cancer who have completed adjuvant trastuzumab-based therapy. NERLYNX has been shown
December 11, 2018
World-First Approval for Multiple Myeloma Drug Aplidin®
Singapore, 11 December 2018: Australian multiple myeloma patients will have world-first access to a new first-in-class drug developed to treat the disease, following approval by Australian regulatory authorities. The drug, APLIDIN (plitidepsin) will be available to patients who have failed or are resistant to other therapies, after the Therapeutic Goods Administration (TGA) decision to approve APLIDIN
November 1, 2018
Specialised Therapeutics to Collaborate with Pharmacy Phusion to Improve Patient Outcomes
Singapore, 2 November 2018: Independent pharmaceutical company Specialised Therapeutics (ST) has struck a new agreement with specialty pharmacy services group Pharmacy Phusion to assist with the distribution and patient support for a new medicine that treats HER2 overexpressing early-stage breast cancer. Under the terms of the agreement, patients prescribed this new breast cancer treatment by
August 27, 2018
Specialised Therapeutics Celebrates 10 Years and Unveils Expansion Plan
Melbourne, Australia 27 August 2018: Privately-held pharmaceutical company Specialised Therapeutics Australia will today mark its 10th anniversary, unveiling new Australian headquarters and a business plan to drive healthcare innovation over the next decade. The company, which was founded ten years ago by pharmaceutical expats Carlo Montagner and Bozena Zembrzuski with a single chemotherapy product, has
April 5, 2018
Specialised Therapeutics Asia Initiates Early Access Program for Neratinib
Singapore, 5 April 2018: Specialised Therapeutics Asia today announces the initiation of an early access program for neratinib, an extended adjuvant treatment for early-stage HER2-positive (HER2+) breast cancer. Under this Special Access Program (SAP) select patients in Australia will be provided access to the medicine, where appropriate and when permitted by relevant regulatory authorities. The